The pharmaceutical firm’s listing follows an IPO that was oversubscribed more than 137 times, signalling robust investor appetite for healthcare stocks in India.
Shares of Corona Remedies made a “stellar” entry on the stock markets today (Monday 15 December), listing at a premium of more than 38% over the issue price. The Gujarat-based drug maker debuted at ₹1,470 on the National Stock Exchange, way above its initial public offering price of ₹1,062.
On the BSE (Bombay Stock Exchange), the stock opened at ₹1,452, a premium of nearly 37%. The strong debut puts the company’s value at roughly ₹8,880 crore (£815m).
The strong listing wasn’t exactly a surprise after the company’s £61m (₹655 crore) IPO got an overwhelming response last week. The issue was subscribed a massive 137 times, with institutional investors bidding nearly 294 times their allotted quota. Analysts credit the demand to the company’s solid financial health. Corona Remedies reported a 65% jump in net profit for financial year 2025.
The IPO was entirely an “Offer for Sale,” meaning the company didn’t raise fresh capital but let existing investors and promoters sell their stakes. Even so, the market has rewarded the firm’s consistent growth in niche areas like women’s health and cardio-metabolic care.
“The listing has been on expected lines… supported by disciplined capital allocation and a low debt-to-equity ratio,” market analysts noted, pointing to the firm’s attractive return ratios.
Corona Remedies’ debut breaks a recent pattern of underwhelming listings, bringing some fresh optimism to Dalal Street. It joins a select group of pharma companies that delivered strong listing gains in 2025, showing investors are still willing to pay up for companies with clean balance sheets and clear growth potential.
After the initial surge, the stock cooled off a bit in intraday trading, hovering around ₹1,422 on the NSE by mid-afternoon. Market experts are saying that while the listing pop is great for short-term traders, long-term investors should keep an eye on the company’s quarterly earnings to see if it can actually maintain this high valuation.
Also Read / Divided Federal Reserve cuts rates again but signals slower path ahead.
Leave a comment